Is kesimpta an infusion or a self injection?

Is Kesimpta given as an infusion or an injection?

Kesimpta is supplied as a pre-filled syringe or auto-injector pen that patients use for a once-monthly self-injection under the skin. It is never given as an intravenous infusion.

Who makes Kesimpta and what is the dosing schedule?

Novartis manufactures Kesimpta. The regimen starts with three weekly 20 mg injections, followed by a monthly 20 mg maintenance injection. Patients can give the dose themselves at home after brief training.

What happens if a patient misses a dose?

A missed dose should be taken as soon as remembered and then the monthly schedule resumes from that new date. If more than a month has passed, patients should consult their prescriber to re-establish the regimen.

How does Kesimpta compare with other MS treatments like Ocrevus?

Ocrevus is given as an intravenous infusion every six months after initial doses. Kesimpta offers the convenience of at-home monthly injections, whereas Ocrevus requires clinic visits. Both target CD20-positive B cells, but they differ in administration, dosing frequency, and monitoring requirements.

Can patients switch from an infusion therapy to Kesimpta?

Switching is possible after discussion with a neurologist. The physician will determine the wash-out period based on the prior drug’s half-life and immune effects, then start the Kesimpta loading doses.

When does Kesimpta’s patent expire?

The key U.S. composition-of-matter patent is set to expire in 2031, with possible extensions. DrugPatentWatch.com tracks these dates and any related litigation or exclusivity periods.

Are biosimilars or generics available yet?

No approved biosimilar or generic version of ofatumumab (Kesimpta) exists in the United States. Market entry is unlikely before the primary patent and regulatory exclusivity periods lapse.